<SEC-DOCUMENT>0001193125-21-350771.txt : 20211208
<SEC-HEADER>0001193125-21-350771.hdr.sgml : 20211208
<ACCEPTANCE-DATETIME>20211208060813
ACCESSION NUMBER:		0001193125-21-350771
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20211208
FILED AS OF DATE:		20211208
DATE AS OF CHANGE:		20211208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		211477576

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d215408d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> UNDER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of December 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT>
&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Long</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">John Long</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December&nbsp;8, 2021 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit Index </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.1&#151;Press Release </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d215408dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g215408g09q67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> to Pursue Dual Listing Plan on The Main Board of The Stock
Exchange of Hong Kong Limited </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHANGHAI, China &#150; December&nbsp;7, 2021 &#150;</B> <FONT STYLE="white-space:nowrap">I-Mab</FONT> (the
&#147;Company&#148;) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Board of Directors of the Company (the &#147;Board&#148;)
approved a motion to pursue the listing of the Company&#146;s ordinary shares on The Main Board of The Stock Exchange of Hong Kong Limited (the &#147;Hong Kong Dual Listing&#148;). The Board also authorized the Company&#146;s senior management to
proceed with the relevant preparatory work and undertake the necessary procedures to complete the Hong Kong Dual Listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Hong Kong Dual listing is
conditional upon and subject to, among other things, market conditions, further approval of the Board, and the obtaining of the necessary regulatory approvals. The Company will make further announcement(s) to disclose any material updates and
progress with respect to the Hong Kong Dual Listing in accordance with applicable laws and regulations as and when appropriate. This announcement is for information purposes only and does not constitute, or form part of, any invitation or offer to
acquire, purchase or subscribe to any securities of the Company. Shareholders and potential investors should exercise caution when dealing in the securities of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
<FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB) is an innovation-driven global biopharma
company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology and autoimmune diseases. The Company&#146;s mission is to bring transformational medicines to patients around the
world through innovation. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> globally competitive pipeline of more than 20 clinical and preclinical-stage drug candidates is driven by its internal discovery and global partnerships for <FONT
STYLE="white-space:nowrap">in-licensing,</FONT> based on the Company&#146;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Proof-of-Concept</FONT></FONT></FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> development strategies. The Company is progressing from a clinical-stage biotech company into a fully integrated global biopharmaceutical company with cutting-edge R&amp;D capabilities, a
world-class GMP manufacturing facility, and commercial capability. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and
Maryland and San Diego in the United States. For more information, please visit <FONT STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT> and follow <FONT STYLE="white-space:nowrap">I-Mab</FONT> on LinkedIn, Twitter , and WeChat. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shanghai (HQ)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">88 Shangke Road, Pudong New District</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shanghai,
China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 710, 9801
Washingtonian Blvd Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"><U>www.i-mabbiopharma.com</U></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g215408g09q67.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement contains forward-looking statements. These statements are made under the &#147;safe harbor&#148; provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as &#147;will,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;future,&#148; &#147;intends,&#148; &#147;plans,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;confident&#148; and similar statements. <FONT STYLE="white-space:nowrap">I-Mab</FONT> may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and
Exchange Commission (the &#147;SEC&#148;), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical
facts, including statements about <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause
actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to demonstrate the safety and efficacy of its drug
candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> drug candidates; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to achieve commercial success for its drug candidates, if approved; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT>
ability to obtain and maintain protection of intellectual property for its technology and drugs; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> reliance on third parties to conduct drug development, manufacturing and other services; <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> limited operating history and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain additional funding for operations and to complete the development and commercialization of its drug
candidates; and the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s clinical development, commercial and other operations, as well as those risks more fully discussed in the &#147;Risk Factors&#148;
section in <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well as discussions of potential risks, uncertainties, and other important factors in <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to <FONT STYLE="white-space:nowrap">I-Mab,</FONT> and <FONT
STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> Contacts </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">John Long <BR>Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">john.long@i-mabbiopharma.com</FONT></U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gigi Feng <BR>Chief Communications Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT
STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT></U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+86 21 6057 8000</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Piacente Group, Inc.</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Emilie Wu </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:</FONT> <U>emilie@thepiacentegroup.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6039 8363 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shanghai (HQ)</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suites 802, 505, 702, West
Tower</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">88 Shangke Road, Pudong New District</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shanghai,
China</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 710, 9801
Washingtonian Blvd Gaithersburg</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Maryland 20878</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"><U>www.i-mabbiopharma.com</U></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g215408g09q67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g215408g09q67.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M2N0PZ;86TOFP65O%)TW)$JG\P*IU)R5FV3&C2B[QBE\BU69J% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
:!0 4 % !0 4 % !0 4 % !0 4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
